Table 4.

Odds ratios for severe COVID-19 (hospitalization or death) by outpatient SARS-CoV-2 treatment status.

Comparisons (reference=second group listed)	Unadjusted OR for severe COVID-19 (95%CI)	Multivariable* OR for severe COVID-19 (95%CI)
Primary analysis
Any outpatient treatment vs. no outpatient treatment	0.10 (0.05, 0.21)	0.12 (0.05, 0.25)
Secondary analyses
Nirmatrelvir/ritonavir vs. no outpatient treatment	0.06 (0.02, 0.17)	0.08 (0.03, 0.24)
Monoclonal antibodies vs. no outpatient treatment	0.23 (0.09, 0.60)	0.20 (0.07, 0.54)
Nirmatrelvir/ritonavir vs. all others	0.08 (0.03, 0.23)	0.12 (0.04, 0.34)
Monoclonal antibodies vs. all others	0.52 (0.20, 1.32)	0.35 (0.13, 0.97)
Nirmatrelvir/ritonavir vs. monoclonal antibodies	0.26 (0.07, 1.00)	0.46 (0.11, 1.97)

^*Adjusted for continuous age, continuous Charlson Comorbidity Index, continuous estimated glomerular filtration rate, and race.

CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.